EGFR and non-small cell lung carcinoma: In phase II trials, toripalimab and tislelizumab were reported to have objective response rates (ORRs) of 50.0% and 59.4% and disease control rates (DCRs) of 87.5% and 90.6%, respectively, in combination with chemotherapy as second-line treatment in pretreated EGFR-mutated advanced NSCLC (21, 22).